AIRSAirSculpt Technologies, Inc.
The Read
4% median absolute stock move around AirSculpt-related catalysts, driven by management’s announcements of stabilized sales, sequential growth, and key business turning points that exceeded EPS expectations.
The schedule
- Wed20Jan
A potential strategic review period focusing on institutional portfolio adjustments and balance sheet optimization heading into the new year.
- Fri5Feb
Q3 2026 earnings where the market expects updated 2027 outlooks and stabilization of the core body contouring demand.
- Sun14Feb
Q4 2026 earnings release and full-year 2027 guidance, serving as a critical test for normalized run-rates and combined therapy adoption.
- Fri7May
Q1 2027 earnings release, capturing early seasonal aesthetic demand heading into the peak summer months.
Past
- Tue15Sep
An industry conference providing management a platform for updates on capital allocation and GLP-1 defensive strategies.
- Fri7Aug
Actual outcome: Bear · $3.22 at outcome
AirSculpt reported an EPS of -0.0345, matching expectations, but the stock fell sharply as the broader market sentiment turned negative. The company highlighted stabilization in its core business and expansion into GLP-1 services, but the overall market environment and leverage concerns pressured the stock below the bear floor.
AirSculpt's Q2 2026 earnings will test if the positive same-center sales from Q1 were sustainable or a temporary blip. At 12.6x Net Debt/EBITDA, leverage remains a critical overhang.
- Mon15Jun
Actual outcome: Bear · $4.42 at outcome
No relevant updates regarding AirSculpt's clinic utilization or GLP-1 strategy were released during the event window. Without reassuring data to address ongoing concerns about the impact of GLP-1 weight-loss therapies on its body contouring demand, investor sentiment remained negative, driving the stock down 13.0% to the bear floor.
AirSculpt is anticipated to provide interim insights into clinic utilization and its strategic positioning alongside GLP-1 weight-loss therapies.
- Fri8May
Actual outcome: Bull · $5.38 at outcome
AirSculpt Technologies reported Q1 2026 earnings that met EPS expectations, but the stock surged 39.4% as management declared the quarter a 'key turning point.' The massive rally was driven by clear signs of a successful turnaround, specifically stabilized revenue, the company's first positive same-center sales result in over two years, and continued debt reduction.
First quarter earnings report and management update on early 2026 clinic performance.
- Tue31Mar
Actual outcome: Bull · $2.72 at outcome
AirSculpt Technologies reported Q4 2025 earnings that met EPS expectations at -$0.03. The stock ultimately rallied to exceed the bull target, driven by management's commentary that strategic initiatives have stabilized the business and returned same-store sales to growth entering fiscal 2026. This sequential improvement in same-store sales trends fueled strong bullish momentum, overshadowing a minor subsequent correction regarding a non-cash adjustment for a facility closure.
Release of fiscal year-end results and management's outlook for 2026 consumer demand.
